Organization (Academic)
Morehouse School of Medicine
ClinicalTrials.gov lists Morehouse School of Medicine as lead sponsor of 22 trials. It has 3 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Morehouse School of Medicine: 22 lead-sponsored trials and 1 legal-entity registration.
Disease areas (26)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 7 |
| COVID-19 | 2 |
| Colorectal Neoplasms | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Epilepsy | 2 |
Showing 5 of 26 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 2 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
Showing 10 of 16 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 9 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| DPP | Diabetes Mellitus | Phase 2/3 | 1 |
| DPP | Prediabetic State | Phase 2/3 | 1 |
| DPP | Weight Loss | Phase 2/3 | 1 |
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Sulfave | 1 |
| Sutab | 1 |
| Polyethylene Glycol 3350 | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 20% on time (n=5) |
Journals published in (74)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of family medicine | 2 |
| Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine | 2 |
| Diabetes care | 2 |
| Diabetologia | 2 |
| International journal of sport nutrition and exercise metabolism | 2 |
Showing 5 of 74 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 112 | 28 | 2025-10-28 |
Financing and grant events (166)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-26 | NIH grant | 473,497 | Reporter |
| 2025-09-24 | NIH grant | 1,000,000 | Reporter |
| 2025-09-18 | NIH grant | 248,802 | Reporter |
| 2025-09-17 | NIH grant | 605,996 | Reporter |
| 2025-09-11 | NIH grant | 201,683 | Reporter |
Showing 5 of 166 events.
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 2 |
| University System of Georgia | Co sponsors trial with | 1 |
| Emory University | Co sponsors trial with | 1 |
| Janssen Scientific Affairs (United States) | Co sponsors trial with | 1 |
Latest dated events (307)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-28 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 307 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| MOREHOUSE SCHOOL OF MEDICINE | Certificate of waiver | Active |
| MOREHOUSE SCHOOL OF MEDICINE | Certificate of compliance | Terminated |
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CYP24A1 | Trial collaborator | Mentioned in trial text |
| CYP27A1 | Trial collaborator | Mentioned in trial text |
| PTH | Trial collaborator | Mentioned in trial text |
| VDR | Trial collaborator | Mentioned in trial text |
Biomarkers this organization publishes on (109)
Shown in this order: most publications first.
Showing 5 of 109 biomarkers.
On Scientist.com
Morehouse School of Medicine is linked to 4 research suppliers in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.
Work with Morehouse School of Medicine Analytic Protein Lab on Scientist.com
For prices, more details, or to contact Morehouse School of Medicine Analytic Protein Lab, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.